View source for 18558882. DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS simplified abstract (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM)

=DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS=


==Organization Name==

[[:Category:BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM|BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM]]


[[Category:BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM]]

==Inventor(s)==

[[:Category:Kytai Nguyen of Austin TX (US)|Kytai Nguyen of Austin TX (US)]][[Category:Kytai Nguyen of Austin TX (US)]]

[[:Category:Jon Weidanz of Austin TX (US)|Jon Weidanz of Austin TX (US)]][[Category:Jon Weidanz of Austin TX (US)]]

[[:Category:Serkan Yaman of Austin TX (US)|Serkan Yaman of Austin TX (US)]][[Category:Serkan Yaman of Austin TX (US)]]

[[:Category:Harish Ramachandramoorthy of Arlington TX (US)|Harish Ramachandramoorthy of Arlington TX (US)]][[Category:Harish Ramachandramoorthy of Arlington TX (US)]]

[[:Category:Manoj Kumar Sabnani of Arlington TX (US)|Manoj Kumar Sabnani of Arlington TX (US)]][[Category:Manoj Kumar Sabnani of Arlington TX (US)]]

==DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18558882 titled 'DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS

**Simplified Explanation:**
The patent application describes CAR-T MNP compositions and methods for targeted therapeutic delivery using engineered T lymphocyte membrane-coated nanoparticles.

**Key Features and Innovation:**
* Chimeric antigen receptor (CAR) engineered T lymphocyte membrane-coated nanoparticles.
* Targeted delivery of therapeutics to specific targets.
* Utilizes the unique properties of T lymphocytes for drug delivery.

**Potential Applications:**
The technology can be used in targeted drug delivery for various diseases such as cancer, autoimmune disorders, and infectious diseases.

**Problems Solved:**
The technology addresses the challenge of targeted drug delivery to specific cells or tissues while minimizing off-target effects.

**Benefits:**
* Enhanced precision in drug delivery.
* Reduced side effects.
* Improved therapeutic outcomes.

**Commercial Applications:**
The technology has potential applications in the pharmaceutical industry for developing targeted therapies and personalized medicine approaches.

**Questions about CAR-T MNP:**
1. How does the engineered T lymphocyte membrane enhance the targeted delivery of therapeutics?
2. What are the potential limitations of using CAR-T MNP technology in clinical settings?


==Original Abstract Submitted==

Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.



[[Category:A61K35/17]]
[[Category:A61K9/16]]
[[Category:A61K39/00]]
[[Category:C07K14/725]]
[[Category:C07K16/32]]
[[Category:CPC_A61K35/17]]